House Roll Call

H.R.1048

Roll 80 • Congress 119, Session 1 • Mar 27, 2025 10:34 AM • Result: Failed

← Back to roll call listView bill pageClerk recordAPI source

BillH.R.1048 — DETERRENT Act
Vote questionOn Agreeing to the Amendment
Vote typeRecorded Vote
ResultFailed
TotalsYea 92 / Nay 321 / Present 0 / Not Voting 23
PartyYeaNayPresentNot Voting
R9212008
D0201015
I0000

Research Brief

On Agreeing to the Amendment

Bill Analysis

Summary of HR 1048 - DETERRENT Act

The DETERRENT Act, introduced in the 119th Congress as HR 1048, aims to enhance the accountability of pharmaceutical companies regarding the pricing of prescription drugs. Specifically, the bill seeks to deter excessive price increases by imposing penalties on drug manufacturers that raise prices beyond a specified threshold.

Key Provisions: The DETERRENT Act establishes a framework for monitoring and regulating price increases of prescription drugs covered under Medicare and Medicaid. It mandates that pharmaceutical companies report price increases to the Department of Health and Human Services (HHS) and provides HHS the authority to impose financial penalties on companies that exceed a defined annual price increase limit.

Funding and Authorities: The bill authorizes HHS to allocate resources necessary for the enforcement of these regulations, including the establishment of a monitoring system to track drug prices. The penalties collected from non-compliant manufacturers would be directed to a fund aimed at supporting health programs for low-income individuals.

Programs and Agencies Affected: The primary agencies impacted by the DETERRENT Act include HHS, the Centers for Medicare & Medicaid Services (CMS), and the Food and Drug Administration (FDA). The act directly affects pharmaceutical companies that produce drugs covered under federal health programs.

Beneficiaries and Regulation: The act is designed to benefit Medicare and Medicaid beneficiaries by potentially lowering out-of-pocket costs for prescription medications. It aims to regulate pharmaceutical companies by holding them accountable for unjustified price hikes, thereby promoting fair pricing practices within the industry.

Key Timelines: Following its introduction, HR 1048 was received in the Senate, read twice, and referred to the Senate Committee on Health, Education, Labor, and Pensions for further consideration. The timeline for subsequent actions will depend on the committee’s review and any potential amendments before a Senate vote.

Overall, the DETERRENT Act represents a significant legislative effort to address rising prescription drug costs and enhance transparency in pharmaceutical pricing.

Yea (92)

S
Scott Franklin

FL • R • Aye

M
Mark Green

TN • R • Aye

D
David Schweikert

AZ • R • Aye

Nay (321)

K
Ken Calvert

CA • R • No

G
Gerald Connolly

VA • D • No

J
Jason Crow

CO • D • No

L
Lloyd Doggett

TX • D • No

J
John Mannion

NY • D • No

L
Lisa McClain

MI • R • No

J
John Rutherford

FL • R • No

P
Pete Sessions

TX • R • No

E
Eric Swalwell

CA • D • No

R
Rashida Tlaib

MI • D • No

N
Nydia Velázquez

NY • D • No

D
Debbie Wasserman Schultz

FL • D • No

Not Voting (23)

J
John Garamendi

CA • D • Not Voting

L
Lucy McBath

GA • D • Not Voting